BofA Notes Positive Interest in Novavax, Inc. (NVAX) Technology Despite Timing Concerns for Licensed Assets

TheFly reported connected January 20 that BofA raised its terms people connected NVAX to $7 from $6 portion maintaining an Underperform rating. The update followed the company’s announcement of a non-exclusive licensing woody with Pfizer for its Matrix-M adjuvant crossed up to 2 infectious illness areas. While BofA views the statement and upfront outgo arsenic affirmative signs of involvement successful Novavax, Inc. (NASDAQ:NVAX)’s technology, the steadfast remains cautious astir the timing of improvement for assets nether the licence and continues to complaint the banal Underperform.

Additionally, connected January 21, NVAX saw unusually beardown bullish options activity, with telephone trading moving astatine astir 3 times mean levels. Implied volatility jumped by astir 8 points to supra 71%, portion the put/call ratio fell to 0.07, reflecting beardown upside positioning up of the company’s expected net aboriginal successful February.

Novavax, Inc. (NASDAQ:NVAX) is simply a U.S. biotechnology institution processing and commercializing innovative vaccines against superior infectious diseases utilizing its recombinant macromolecule level and Matrix‑M adjuvant. Its portfolio includes COVID‑19 vaccines and pipeline candidates for influenza and combo vaccines, supported by strategical partnerships to grow planetary wellness impact.

While we admit the imaginable of NVAX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.